- Results from Medtronic's (MDT +1.2%) MINERVA clinical study show that its ATP algorithm reduces the development of persistent atrial fibrillation by 58% compared to standard pacemakers. The algorithm restores the heart back to its normal rhythm by pacing during abnormally fast atrial rhythms. In the study, it played a significant role in slowing the progression of the disease by successfully terminating atrial tachycardia/atrial fibrillation episodes.
- The company believes that the reduction in these episodes could save $1,218 in healthcare costs per patient over a 10-year time frame.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Thu, 5:10PM)
at Zacks.com (Tue, 4:53PM)
UPDATE: Medtronic plc: FDA Approves the VenaSeal Closure System for Treatment of Clinically Symptomatic Venous Refluxat Benzinga.com (Tue, 1:02PM)
at Zacks.com (Feb 23, 2015)
at Investor's Business Daily (Feb 19, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs